Cargando…

Development and Optimization of Chitosan Nanoparticle-Based Intranasal Vaccine Carrier

Chitosan is a natural polysaccharide, mainly derived from the shell of marine organisms. At present, chitosan has been widely used in the field of biomedicine due to its special characteristics of low toxicity, biocompatibility, biodegradation and low immunogenicity. Chitosan nanoparticles can be ea...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Xiaoyi, Liu, Nan, Wang, Zengming, Gao, Jing, Zhang, Hui, Li, Meng, Du, Yimeng, Gao, Xiang, Zheng, Aiping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8746444/
https://www.ncbi.nlm.nih.gov/pubmed/35011436
http://dx.doi.org/10.3390/molecules27010204
_version_ 1784630587418476544
author Gao, Xiaoyi
Liu, Nan
Wang, Zengming
Gao, Jing
Zhang, Hui
Li, Meng
Du, Yimeng
Gao, Xiang
Zheng, Aiping
author_facet Gao, Xiaoyi
Liu, Nan
Wang, Zengming
Gao, Jing
Zhang, Hui
Li, Meng
Du, Yimeng
Gao, Xiang
Zheng, Aiping
author_sort Gao, Xiaoyi
collection PubMed
description Chitosan is a natural polysaccharide, mainly derived from the shell of marine organisms. At present, chitosan has been widely used in the field of biomedicine due to its special characteristics of low toxicity, biocompatibility, biodegradation and low immunogenicity. Chitosan nanoparticles can be easily prepared. Chitosan nanoparticles with positive charge can enhance the adhesion of antigens in nasal mucosa and promote its absorption, which is expected to be used for intranasal vaccine delivery. In this study, we prepared chitosan nanoparticles by a gelation method, and modified the chitosan nanoparticles with mannose by hybridization. Bovine serum albumin (BSA) was used as the model antigen for development of an intranasal vaccine. The preparation technology of the chitosan nanoparticle-based intranasal vaccine delivery system was optimized by design of experiment (DoE). The DoE results showed that mannose-modified chitosan nanoparticles (Man-BSA-CS-NPs) had high modification tolerance and the mean particle size and the surface charge with optimized Man-BSA-CS-NPs were 156 nm and +33.5 mV. FTIR and DSC results confirmed the presence of Man in Man-BSA-CS-NPs. The BSA released from Man-BSA-CS-NPs had no irreversible aggregation or degradation. In addition, the analysis of fluorescence spectroscopy of BSA confirmed an appropriate binding constant between CS and BSA in this study, which could improve the stability of BSA. The cell study in vitro demonstrated the low toxicity and biocompatibility of Man-BSA-CS-NPs. Confocal results showed that the Man-modified BSA-FITC-CS-NPs promote the endocytosis and internalization of BSA-FITC in DC2.4 cells. In vivo studies of mice, Man-BSA-CS-NPs intranasally immunized showed a significantly improvement of BSA-specific serum IgG response and the highest level of BSA-specific IgA expression in nasal lavage fluid. Overall, our study provides a promising method to modify BSA-loaded CS-NPs with mannose, which is worthy of further study.
format Online
Article
Text
id pubmed-8746444
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87464442022-01-11 Development and Optimization of Chitosan Nanoparticle-Based Intranasal Vaccine Carrier Gao, Xiaoyi Liu, Nan Wang, Zengming Gao, Jing Zhang, Hui Li, Meng Du, Yimeng Gao, Xiang Zheng, Aiping Molecules Article Chitosan is a natural polysaccharide, mainly derived from the shell of marine organisms. At present, chitosan has been widely used in the field of biomedicine due to its special characteristics of low toxicity, biocompatibility, biodegradation and low immunogenicity. Chitosan nanoparticles can be easily prepared. Chitosan nanoparticles with positive charge can enhance the adhesion of antigens in nasal mucosa and promote its absorption, which is expected to be used for intranasal vaccine delivery. In this study, we prepared chitosan nanoparticles by a gelation method, and modified the chitosan nanoparticles with mannose by hybridization. Bovine serum albumin (BSA) was used as the model antigen for development of an intranasal vaccine. The preparation technology of the chitosan nanoparticle-based intranasal vaccine delivery system was optimized by design of experiment (DoE). The DoE results showed that mannose-modified chitosan nanoparticles (Man-BSA-CS-NPs) had high modification tolerance and the mean particle size and the surface charge with optimized Man-BSA-CS-NPs were 156 nm and +33.5 mV. FTIR and DSC results confirmed the presence of Man in Man-BSA-CS-NPs. The BSA released from Man-BSA-CS-NPs had no irreversible aggregation or degradation. In addition, the analysis of fluorescence spectroscopy of BSA confirmed an appropriate binding constant between CS and BSA in this study, which could improve the stability of BSA. The cell study in vitro demonstrated the low toxicity and biocompatibility of Man-BSA-CS-NPs. Confocal results showed that the Man-modified BSA-FITC-CS-NPs promote the endocytosis and internalization of BSA-FITC in DC2.4 cells. In vivo studies of mice, Man-BSA-CS-NPs intranasally immunized showed a significantly improvement of BSA-specific serum IgG response and the highest level of BSA-specific IgA expression in nasal lavage fluid. Overall, our study provides a promising method to modify BSA-loaded CS-NPs with mannose, which is worthy of further study. MDPI 2021-12-29 /pmc/articles/PMC8746444/ /pubmed/35011436 http://dx.doi.org/10.3390/molecules27010204 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Gao, Xiaoyi
Liu, Nan
Wang, Zengming
Gao, Jing
Zhang, Hui
Li, Meng
Du, Yimeng
Gao, Xiang
Zheng, Aiping
Development and Optimization of Chitosan Nanoparticle-Based Intranasal Vaccine Carrier
title Development and Optimization of Chitosan Nanoparticle-Based Intranasal Vaccine Carrier
title_full Development and Optimization of Chitosan Nanoparticle-Based Intranasal Vaccine Carrier
title_fullStr Development and Optimization of Chitosan Nanoparticle-Based Intranasal Vaccine Carrier
title_full_unstemmed Development and Optimization of Chitosan Nanoparticle-Based Intranasal Vaccine Carrier
title_short Development and Optimization of Chitosan Nanoparticle-Based Intranasal Vaccine Carrier
title_sort development and optimization of chitosan nanoparticle-based intranasal vaccine carrier
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8746444/
https://www.ncbi.nlm.nih.gov/pubmed/35011436
http://dx.doi.org/10.3390/molecules27010204
work_keys_str_mv AT gaoxiaoyi developmentandoptimizationofchitosannanoparticlebasedintranasalvaccinecarrier
AT liunan developmentandoptimizationofchitosannanoparticlebasedintranasalvaccinecarrier
AT wangzengming developmentandoptimizationofchitosannanoparticlebasedintranasalvaccinecarrier
AT gaojing developmentandoptimizationofchitosannanoparticlebasedintranasalvaccinecarrier
AT zhanghui developmentandoptimizationofchitosannanoparticlebasedintranasalvaccinecarrier
AT limeng developmentandoptimizationofchitosannanoparticlebasedintranasalvaccinecarrier
AT duyimeng developmentandoptimizationofchitosannanoparticlebasedintranasalvaccinecarrier
AT gaoxiang developmentandoptimizationofchitosannanoparticlebasedintranasalvaccinecarrier
AT zhengaiping developmentandoptimizationofchitosannanoparticlebasedintranasalvaccinecarrier